FIG 6.

IFN-α protects HIV-infected and bystander MDM from MG1 infection and killing in a dose-dependent manner. (A) To assess the effect of IFN-I on MG1 infection of HSA⁻ and HSA⁺ MDM, cells were pretreated with increasing doses of IFN-α 24 h prior to MG1 infection. Frequencies of GFP⁺ MDM within HSA⁻ and HSA⁺ cell populations at 48h post-MG1 infection were then measured by flow cytometry (n = 6; P < 0.0001 by 2-way repeated-measures ANOVA; *, P < 0.05, **, P < 0.01 by Bonferroni posttest.). (B) Proviral HIV-1 DNA, measured relative to MG1-uninfected control, at 48 h post-MG1 infection. MDM were pretreated with IFN-α 24 h prior to MG1 infection (n = 7; P values were calculated by paired, two-tailed t test). Data represent mean ± SEM; n values represent separate biological replicates.